These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27379680)

  • 1. Evolution of the Treatments for Hemophilia.
    Guelcher CJ
    J Infus Nurs; 2016; 39(4):218-24. PubMed ID: 27379680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The management of hemophilia patients with inhibitors.
    Nilsson IM
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract]   [Full Text] [Related]  

  • 3. The history of hemophilia.
    Franchini M; Mannucci PM
    Semin Thromb Hemost; 2014 Jul; 40(5):571-6. PubMed ID: 24911674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive care for hemophilia and other inherited bleeding disorders.
    Page D
    Transfus Apher Sci; 2019 Oct; 58(5):565-568. PubMed ID: 31427262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 6. The past and future of haemophilia: diagnosis, treatments, and its complications.
    Peyvandi F; Garagiola I; Young G
    Lancet; 2016 Jul; 388(10040):187-97. PubMed ID: 26897598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to manage invasive procedures in children with haemophilia.
    Ljung RC; Knobe K
    Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
    Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 10. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis in real life scenarios.
    Fischer K; Konkle B; Broderick C; Kessler CM
    Haemophilia; 2014 May; 20 Suppl 4():106-13. PubMed ID: 24762285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic factor replacement in hemophilia.
    Carcao MD; Aledort L
    Blood Rev; 2004 Jun; 18(2):101-13. PubMed ID: 15010149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current issues in prophylactic therapy for persons with hemophilia.
    Dunn AL; Abshire TC
    Acta Haematol; 2006; 115(3-4):162-71. PubMed ID: 16549891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R; Gretenkort Andersson N
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current state of adverse event reporting in hemophilia.
    van Vulpen LF; Saccullo G; Iorio A; Makris M
    Expert Rev Hematol; 2017 Feb; 10(2):161-168. PubMed ID: 28013565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of implantable venous access devices in children with severe hemophilia: benefits and burden.
    Van Dijk K; Van Der Bom JG; Bax KN; Van Der Zee DC; Van Den Berg MH
    Haematologica; 2004 Feb; 89(2):189-94. PubMed ID: 15003894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of factor VIII inhibitors: evolution and current status.
    Bloom AL
    Haemostasis; 1992; 22(5):268-75. PubMed ID: 1478538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.